Eledon Pharmaceuticals, Inc. (ELDN) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
ELDN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ELDN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export ELDN earnings history in CSV or JSON format
Free sign-in required to download data
Eledon Pharmaceuticals, Inc. (ELDN) Earnings Overview
As of May 8, 2026, Eledon Pharmaceuticals, Inc. (ELDN) reported trailing twelve-month net income of -$80M, reflecting -3730.7% year-over-year growth. The company earned $-1.03 per diluted share over the past four quarters.
Looking at the long-term picture, ELDN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2012.
Eledon Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TGTX ($462M net income, 72.6% margin), IMVT (-$464M net income), PRAX (-$327M net income), ELDN has comparable earnings metrics. Compare ELDN vs TGTX →
ELDN Earnings vs Peers
Earnings metrics vs comparable public companies
ELDN Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -26.1% | $0 | $-28.73 | - | - |
| 2024 | -$36M | +69.0% | -$71M | $-0.75 | - | - |
| 2023 | -$117M | -32.5% | -$43M | $-1.64 | - | - |
| 2022 | -$88M | -154.9% | -$40M | $-6.13 | - | - |
| 2021 | -$35M | -51.3% | -$37M | $-2.33 | - | - |
| 2020 | -$23M | -42.5% | -$13M | $-15.72 | - | - |
| 2019 | -$16M | -13.8% | -$14M | $-27.27 | - | - |
| 2018 | -$14M | -7.2% | -$14M | $-28.11 | - | - |
| 2017 | -$13M | +65.4% | -$13M | $-50.47 | - | - |
| 2016 | -$38M | +15.8% | -$38M | $-1785.21 | - | - |
See ELDN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELDN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELDN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELDN — Frequently Asked Questions
Quick answers to the most common questions about buying ELDN stock.
Is ELDN growing earnings?
ELDN EPS fell to $-1.03, with earnings declining -3730.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-80M.
What are ELDN's profit margins?
Eledon Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ELDN's earnings?
ELDN earnings data spans 2012-2025. The declining earnings trend is -3730.7% YoY. Historical data enables comparison across business cycles.